Evidence map›Paper›PMID 31673819›Full record

ArticleHuman genetics2019

Differential phenotypic expression of a novel PDHA1 mutation in a female monozygotic twin pair.

Alejandro Horga, Catherine E Woodward, Alberto Mills, Isabel Pareés, Iain P Hargreaves, Ruth M Brown, Enrico Bugiardini, Tony Brooks, Andreea Manole, Elena Remzova and 10 more

Open access · hybridAbstract readCase ReportsTwin Study
In one paragraph

Article in Human genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Dosage Compensation in Females with X-Linked Metabolic Disorders.International journal of molecular sciences · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Alejandro HorgaDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Catherine E WoodwardNeurogenetics Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
Alberto MillsArea of Pharmacology, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain.
Isabel PareésSobell Department of Motor Neuroscience and Movement Disorders, UCL Queen Square Institute of Neurology, London, UK.
Iain P HargreavesNeurometabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
Ruth M BrownOxford Medical Genetics Laboratories, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Enrico BugiardiniDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Tony BrooksUCL Genomics, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Andreea ManoleDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Elena RemzovaNeurometabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
Shamima RahmanMetabolic Unit, Great Ormond Street Hospital for Children NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health, London, UK.
Mary M ReillyDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Henry HouldenDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Mary G SweeneyNeurogenetics Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
Garry K BrownOxford Medical Genetics Laboratories, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
James M PolkeNeurogenetics Unit, The National Hospital for Neurology and Neurosurgery, London, UK.
Federico GagoArea of Pharmacology, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Spain.
Matthew J PartonDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Robert D S PitceathlyDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK. r.pitceathly@ucl.ac.uk.ORCID http://orcid.org/0000-0002-6123-4551
Michael G HannaDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK. m.hanna@ucl.ac.uk.
National Hospital for Neurology and Neurosurgery · GBChurchill Hospital · GBUniversidad de Alcalá · ESGreat Ormond Street Hospital for Children NHS Foundation Trust · GBHospital Clínico San Carlos · ESUniversity College London · GB

Funding

Medical Research Council G0802760Medical Research Council G1001253Medical Research Council G108/638Medical Research Council MR/S002065/1Medical Research Council MR/S01165X/1Ministerio de Economía, Industria y Competitividad, Gobierno de España (ES) SAF2015-64629-C2-2-RThe Dunhill Medical Trust R605/0717
6 · The paper itself

Abstract

Pyruvate dehydrogenase complex (PDC) deficiency caused by mutations in the X-linked PDHA1 gene has a broad clinical presentation, and the pattern of X-chromosome inactivation has been proposed as a major factor contributing to its variable expressivity in heterozygous females. Here, we report the first set of monozygotic twin females with PDC deficiency, caused by a novel, de novo heterozygous missense mutation in exon 11 of PDHA1 (NM_000284.3: c.1100A>T). Both twins presented in infancy with a similar clinical phenotype including developmental delay, episodes of hypotonia or encephalopathy, epilepsy, and slowly progressive motor impairment due to pyramidal, extrapyramidal, and cerebellar involvement. However, they exhibited clear differences in disease severity that correlated well with residual PDC activities (approximately 60% and 20% of mean control values, respectively) and levels of immunoreactive E1α subunit in cultured skin fibroblasts. To address whether the observed clinical and biochemical differences could be explained by the pattern of X-chromosome inactivation, we undertook an androgen receptor assay in peripheral blood. In the less severely affected twin, a significant bias in the relative activity of the two X chromosomes with a ratio of approximately 75:25 was detected, while the ratio was close to 50:50 in the other twin. Although it may be difficult to extrapolate these results to other tissues, our observation provides further support to the hypothesis that the pattern of X-chromosome inactivation may influence the phenotypic expression of the same mutation in heterozygous females and broadens the clinical and genetic spectrum of PDC deficiency.

Indexed as

MutationX Chromosome InactivationFemaleHumansPedigreePhenotypePrognosisPyruvate Dehydrogenase Complex Deficiency DiseasePyruvate Dehydrogenase (Lipoamide)Twins, Monozygoticpyruvate dehydrogenase E1alpha subunitPyruvate Dehydrogenase (Lipoamide)

Identifiers

PMID31673819
PMCPMC6874639
OpenAlexW2987803261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.